Literature DB >> 20694477

TTF1 expression in normal lung neuroendocrine cells and related tumors: immunohistochemical study comparing two different monoclonal antibodies.

Stefano La Rosa1, Anna Maria Chiaravalli, Claudia Placidi, Nikolaos Papanikolaou, Michele Cerati, Carlo Capella.   

Abstract

Thyroid transcription factor-1 (TTF1) regulates lung morphogenesis and differentiation, and its immunohistochemical expression is used for identifying lung neoplasms. The 8G7G3/1 antibody has been used in previous studies, but a different and more sensitive anti-TTF1 antibody, named SPT24, has become commercially available. Since the immunohistochemical expression of TTF1 in normal lung neuroendocrine (NE) cells has not been previously investigated and its utility in the diagnosis of lung NE tumors is a controversial issue, we studied the TTF1 expression in normal adult and fetal lungs, in 83 pulmonary NE neoplasms, in 131 non-lung NE tumors and in 36 metastases from these neoplasms using these two antibodies. A TTF1 immunoreactivity was demonstrated in normal fetal and adult NE cells when using the SPT24 clone. Conversely, using the 8G7G3/1 antibody, only rare fetal neuroendocrine cells were TTF1 positive while adult NE cells were negative. The SPT24 clone identified TTF1 expression in more carcinoids, most of them peripherally located, and poorly differentiated NE carcinomas than the 8G7G3/1 clone. Non-pulmonary well-differentiated NE tumors were negative for both antibodies. Among the 45 non-pulmonary poorly differentiated NE carcinomas 11% were positive for 8G7G3/1 and 18% for SPT24. TTF1 expression in metastases perfectly reflected that detected in the related primary tumors. Our results indicate that the SPT24 antibody is more sensitive than the 8G7G3/1 clone for labeling lung carcinoids and it appears particularly useful in detecting peripheral neoplasms. In addition, the expression of TTF1 in normal NE cells suggests a possible role for the transcription factor in their development and differentiation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20694477     DOI: 10.1007/s00428-010-0954-0

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  47 in total

1.  A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: use of microwave oven heating to block antibody crossreactivity and retrieve antigens.

Authors:  H Y Lan; W Mu; D J Nikolic-Paterson; R C Atkins
Journal:  J Histochem Cytochem       Date:  1995-01       Impact factor: 2.479

2.  Variable sensitivity and specificity of TTF-1 antibodies in lung metastatic adenocarcinoma of colorectal origin.

Authors:  Eva Compérat; Fan Zhang; Cedric Perrotin; Thierry Molina; Pierre Magdeleinat; Beatrice Marmey; Jean-Francois Régnard; Josee Audouin; Saphie Camilleri-Broët
Journal:  Mod Pathol       Date:  2005-10       Impact factor: 7.842

3.  Expression of thyroid transcription factor-1 in normal and neoplastic lung tissues.

Authors:  Nobuki Nakamura; Eri Miyagi; Shin-ichi Murata; Akira Kawaoi; Ryohei Katoh
Journal:  Mod Pathol       Date:  2002-10       Impact factor: 7.842

4.  Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors.

Authors:  S N Agoff; L W Lamps; A T Philip; M B Amin; R A Schmidt; L D True; A L Folpe
Journal:  Mod Pathol       Date:  2000-03       Impact factor: 7.842

5.  Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas.

Authors:  W Cheuk; M Y Kwan; S Suster; J K Chan
Journal:  Arch Pathol Lab Med       Date:  2001-02       Impact factor: 5.534

Review 6.  Transcriptional control of lung morphogenesis.

Authors:  Yutaka Maeda; Vrushank Davé; Jeffrey A Whitsett
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

7.  Large cell and small cell neuroendocrine bladder carcinoma: immunohistochemical and outcome study in a single institution.

Authors:  Francisco Alijo Serrano; Nora Sánchez-Mora; José Angel Arranz; Carlos Hernández; Emilio Alvarez-Fernández
Journal:  Am J Clin Pathol       Date:  2007-11       Impact factor: 2.493

Review 8.  Primary small cell neuroendocrine carcinoma of the kidney: morphological, immunohistochemical, ultrastructural, and cytogenetic study of a case and review of the literature.

Authors:  Stefano La Rosa; Barbara Bernasconi; Donata Micello; Giovanna Finzi; Carlo Capella
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

9.  Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors.

Authors:  A L Folpe; A M Gown; L W Lamps; R Garcia; D H Dail; R J Zarbo; R A Schmidt
Journal:  Mod Pathol       Date:  1999-01       Impact factor: 7.842

10.  The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specific marker of pancreatic acinar cell carcinoma and pancreatic metaplasia.

Authors:  Stefano La Rosa; Francesca Franzi; Silvia Marchet; Giovanna Finzi; Moira Clerici; Davide Vigetti; Anna Maria Chiaravalli; Fausto Sessa; Carlo Capella
Journal:  Virchows Arch       Date:  2008-12-09       Impact factor: 4.064

View more
  23 in total

Review 1.  Breast metastasis as the first clinical manifestation of ileal neuroendocrine tumor. A challenging diagnosis with relevant clinical implications.

Authors:  Stefano La Rosa; Selenia Casnedi; Roberta Maragliano; Gilles Goyault; Jean-Christophe Weber; Bernard Louis; Elvire Schlund; Fausto Sessa
Journal:  Endocr Pathol       Date:  2015-05       Impact factor: 3.943

Review 2.  Mixed Neuroendocrine-Nonneuroendocrine Neoplasms (MiNENs): Unifying the Concept of a Heterogeneous Group of Neoplasms.

Authors:  Stefano La Rosa; Fausto Sessa; Silvia Uccella
Journal:  Endocr Pathol       Date:  2016-12       Impact factor: 3.943

Review 3.  Pathology of Neuroendocrine Tumours of the Female Genital Tract.

Authors:  Brooke E Howitt; Paul Kelly; W Glenn McCluggage
Journal:  Curr Oncol Rep       Date:  2017-09       Impact factor: 5.075

Review 4.  Therapeutic biomarkers in lung neuroendocrine neoplasia.

Authors:  Luisella Righi; Marco Volante; Ida Rapa; Simona Vatrano; Giuseppe Pelosi; Mauro Papotti
Journal:  Endocr Pathol       Date:  2014-12       Impact factor: 3.943

Review 5.  Neuroendocrine Pulmonary Tumors of Low, Intermediate and High Grade: Anatomopathological Diagnosis-Prognostic and Predictive Factors.

Authors:  José Manuel Cameselle-Teijeiro; José Antonio Mato Mato; Ovidio Fernández Calvo; Jesús García Mata
Journal:  Mol Diagn Ther       Date:  2018-04       Impact factor: 4.074

Review 6.  Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms.

Authors:  Silvia Uccella; Stefano La Rosa; Marco Volante; Mauro Papotti
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

7.  Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach.

Authors:  Tina Zahel; Sabine Krysa; Esther Herpel; Albrecht Stenzinger; Benjamin Goeppert; Peter Schirmacher; Hans Hoffmann; Philipp A Schnabel; Arne Warth
Journal:  Virchows Arch       Date:  2012-03       Impact factor: 4.064

8.  [Neuroendocrine neoplasms of the gastrointestinal tract. Classification, clinical presentation and diagnosis].

Authors:  C Fottner; M M Weber
Journal:  Internist (Berl)       Date:  2012-02       Impact factor: 0.743

9.  An algorithmic approach utilizing CK7, TTF1, beta-catenin, CDX2, and SSTR2A can help differentiate between gastrointestinal and pulmonary neuroendocrine carcinomas.

Authors:  Sanhong Yu; Jason L Hornick; Raul S Gonzalez
Journal:  Virchows Arch       Date:  2021-03-17       Impact factor: 4.064

10.  Posttranslational modification of β-catenin is associated with pathogenic fibroblastic changes in bronchopulmonary dysplasia.

Authors:  Jennifer M S Sucre; Preethi Vijayaraj; Cody J Aros; Dan Wilkinson; Manash Paul; Bruce Dunn; Susan H Guttentag; Brigitte N Gomperts
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-12-09       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.